Controlled distribution under renewed antitrust scrutiny

New York's Office of the Attorney General asked Turing Pharmaceuticals AG (New York, N.Y.) to respond to reports that the company intentionally restricted its distribution scheme for Daraprim pyrimethamine to prevent generic manufacturers from performing bioequivalency studies. In a letter to Turing, Antitrust Bureau Chief Eric Stock wrote that Turing's actions "may be restraining competition unlawfully."

In September, media reports that Turing increased the price of Daraprim from $13.50 per pill to $750 spurred a backlash (see BioCentury, Sept. 28). ...